ALK and non-small cell lung carcinoma: In our initial publication (15), we reported promising efficacy of the BRICS regimen in 23 patients with PD-L1-negative, EGFR/ALK wild-type advanced NSCLC, achieving an ORR of 74.0%, disease control rate (DCR) of 95.7%, median PFS of 16.0 months, and median OS of 32.7 months (2).